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OBJECTIVE— Impaired glucose tolerance (IGT) and/or impaired fasting glucose (IFG) are
risk factors for diabetes, cardiovascular disease (CVD), and kidney disease. We determined the
effects of ramipril and rosiglitazone on combined and individual CVD and renal outcomes in
people with IGT and/or IFG in the Diabetes REduction Assessment With ramipril and rosiglita-
zone Medication (DREAM) trial.
RESEARCHDESIGNANDMETHODS— A total of 5,269 people aged30 years, with
IGT and/or IFG without known CVD or renal insufficiency, were randomized to 15 mg/day
ramipril versus placebo and 8 mg/day rosiglitazone versus placebo. A composite cardiorenal
outcome and its CVD and renal components were assessed during the 3-year follow-up.
RESULTS— Compared with placebo, neither ramipril (15.7% [412 of 2,623] vs. 16.0% [424
of 2,646]; hazard ratio [HR] 0.98 [95% CI 0.84–1.13]; P 0.75) nor rosiglitazone (15.0% [394
of 2,635] vs. 16.8% [442 of 2,634]; 0.87 [0.75–1.01]; P  0.07) reduced the risk of the
cardiorenal composite outcome. Ramipril had no impact on the CVD and renal components.
Rosiglitazone increased heart failure (0.53 vs. 0.08%; HR 7.04 [95% CI 1.60–31.0]; P 0.01)
but reduced the risk of the renal component (0.80 [0.68–0.93]; P  0.005); prevention of
diabetes was independently associated with prevention of the renal component (P  0.001).
CONCLUSIONS— Ramipril did not alter the cardiorenal outcome or its components. Ros-
iglitazone, which reduced diabetes, also reduced the development of renal disease but not the
cardiorenal outcome and increased the risk of heart failure.
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The Diabetes REduction Assessmentwith ramipril and rosiglitazoneMedication (DREAM) trial ran-
domly allocated people with impaired
fasting glucose (IFG) and/or impaired
glucose tolerance (IGT) without known
cardiovascular disease (CVD) or signifi-
cant renal disease to the ACE inhibitor
ramipril or placebo and the thiazo-
lidinedione rosiglitazone or placebo, ac-
cording to a 2  2 factorial design (1).
After a median 3-year follow-up, ramipril
did not significantly reduce the primary
outcome of diabetes or death compared
with placebo; however, it modestly re-
duced postload glucose levels and in-
creased regression of IGT or IFG to
normoglycemia (2). During the same pe-
riod, rosiglitazone reduced the primary
outcome by 60%, decreased fasting and
postload glucose levels, and increased re-
gression to normoglycemia (3). Neither
medication affected CVD events overall;
however, 0.5% of participants allocated
to rosiglitazone vs. 0.1% of those allo-
cated to placebo developed congestive
heart failure.
IFG and IGT are both risk factors for
CVD (4,5); however, people with IFG or
IGT with CVD were excluded from this
trial because of the known cardiovascular
benefits of ACE inhibitors (6). As such,
few CVD events were expected to accrue
and the protocol prespecified a composite
cardiorenal secondary outcome compris-
ing either cardiovascular or renal events.
The effects of ramipril and rosiglitazone
on this composite outcome and its com-
ponents are described herein.
RESEARCH DESIGN AND
METHODS— The DREAM trial de-
sign has been reported previously (1–3).
Briefly, nondiabetic men and women
aged 30 years with IFG (fasting plasma
glucose between 110 and 126 mg/dl [6.1–
7.0 mmol/l]) and/or IGT (2-h post 75-g
oral load with plasma glucose between
140 and 200 mg/dl [7.8–11.0 mmol/l])
were recruited from 191 centers between
July 2001 and August 2003. Key exclu-
sion criteria were known left ventricular
ejection 40% or congestive heart fail-
ure, documented CVD defined as isch-
emic heart disease, stroke, intermittent
claudication with an ankle/arm pressure
index of 0.8, uncontrolled hyperten-
sion requiring ACE inhibitors or angio-
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tensin-2 receptor blockers, known renal
artery stenosis, known creatinine clear-
ance0.6 ml/s, a serum creatinine2.26
mg/dl (200 mol/l), or clinical protein-
uria. The protocol was approved by each
center’s ethics committee, and all partici-
pants provided written informed consent.
Evaluation, randomization, and
follow-up
At baseline, participants were briefly ex-
amined and answered a standardized
questionnaire regarding their medical
history, current CVD symptoms, medica-
tion use, and cardiovascular and renal
therapies. After randomization, partici-
pants were allocated to either 5 mg/day
ramipril for 2 months, 10 mg/day for 10
months and subsequently 15 mg/day, or
matching placebo and either 4 mg/day
rosiglitazone for 2 months and 8 mg/day
thereafter or matching placebo. Study vis-
its occurred at 2 and 6 months and every
6 months subsequently. The median fol-
low-up period was 3 years.
Clinical events were ascertained at
each visit. Supine resting blood pressure
and heart rate were measured at baseline,
2 months, 12 months, and every 12
months thereafter; electrocardiograms
(ECGs) were recorded at baseline, at 2
years, and at study end. A serum and first-
morning urine sample were taken at base-
line and study end and sent to the central
laboratory for measurement of serum cre-
atinine and a urinary albumin-to-
creatinine ratio. Estimated glomerular
filtration rate (eGFR) was calculated ac-
cording to Cockroft and Gault based on
the participant’s serum creatinine, age,
sex, and weight.
Urine and serum creatinine were
measured with a Roche Hitachi 917 ana-
lyzer, and urine albumin was measured
by a Federal Drug Administration–
approved size exclusion high-perfor-
mance liquid chromatography method.
Because the high-performance liquid
chromatography method detects greater
amounts of albumin in the urine than the
immunoassay and is less likely to under-
estimate albumin fragments in people
with diabetes (7,8) , a lbumin-to-
creatinine ratio thresholds for microalbu-
minuria and clinical proteinuria that
corresponded to immunoassay thresh-
olds of 2.0 and 36 mg/mmol, respectively
(prespecified in the DREAM protocol),
were identified by comparing high-
performance liquid chromatography and
immunoassay analysis of urine from the
Heart Outcome, Prevention Evaluation
(HOPE) (9–11)
Study outcomes
The prespecified composite cardiorenal
outcome included either 1) a composite
cardiovascular outcome defined as the
first occurrence of any cardiovascular
death, successful cardiac resuscitation,
nonfatal myocardial infarction (MI),
stroke, revascularization procedure, new
stable or unstable angina with docu-
mented ischemia, or heart failure or 2) a
composite renal outcome defined as any
of the following: progression from nor-
moalbuminuria to either microalbumin-
uria or proteinuria or from micro-
albuminuria to proteinuria, a decrease in
eGFR of30%, or renal insufficiency re-
quiring dialysis or transplantation. Mi-
croalbuminuria was defined as a single
first-morning albumin-to-creatinine ratio
4.4 mg/mmol and36 mg/mmol. Clin-
ical proteinuria was defined as either an
albumin-to-creatinine ratio 36 mg/
mmol or an adjudicated report of clinical
proteinuria. Regression from microalbu-
minuria to normoalbuminuria was also
assessed.
Cardiovascular death included sud-
den cardiovascular death, death due to
MI, stroke, heart failure, arrhythmia, vas-
cular disease (pulmonary embolism or
aortic rupture), presumed CVD (death
not fulfilling all criteria for MI or stroke),
or death of unknown cause. The diagnosis
of MI required 1) a troponin level that was
at least twice the lower level signifying
necrosis or a creatine kinase MB isoen-
zyme level that was1.5 times the upper-
normal limit or other cardiac enzymes at
least twice the upper-normal limit and 2)
either acute ischemic ECG changes or
ischemic chest pain lasting at least 10
min. The diagnosis of stroke required an
acute localized neurological deficit lasting
at least 24 h and imaging for its etiologic
type. Heart failure required hospitaliza-
tion or an emergency stay during 2 con-
secutive calendar days due to heart failure
with two of the three following criteria: 1)
signs and/or symptoms of heart failure, 2)
radiological evidence of pulmonary con-
gestion, or 3) use of diuretics or inotropes
or vasodilator agents. All events were ad-
judicated by cardiologists and endocri-
no log i s t s b l inded to the s tudy
medications, including three new CVD
cases of angina (one on rosiglitazone
alone, one on ramipril alone, and one on
double placebo) that were not listed in the
original DREAM publications as they oc-
curred during the active phase but were
only identified during the final closeout of
the clinical sites following the posttrial
washout phase.
Statistical analysis
Student’s t test and 2 tests were used for
univariate comparisons of continuous
and categorical variables, respectively.
Participants without urine and serum
samples at the end of the study were con-
sidered to have values that did not differ
from baseline. Individuals for whom CVD
status was unavailable at the final visit
were censored at the time of their last
visit. Cox proportional hazards models
were used to estimate the effect of each of
the study drugs stratified for the other
drug on the hazard ratios (HRs) of CVD
outcomes, and the possibility of statistical
interaction between the two study drugs
on these outcomes was assessed by in-
cluding an interaction term in the model.
HRs and 95% CIs were calculated with
corresponding two-sided P values. The
HRs for cardiorenal and renal outcomes
were calculated using logistic regression
models adjusting for the effect of the other
drug. Cox models for these outcomes
could not be used because the cardiorenal
and renal outcomes were only assessed in
all participants at the end of the study.
Logistic regression models were also con-
structed to determine whether prevention
of diabetes with rosiglitazone may have
also prevented the composite renal out-
come (the dependent variable). In the first
model, incident diabetes (during the
DREAM median follow-up period of 3
years) and rosiglitazone allocation were
included as independent variables. In the
second model, diabetes was replaced by
time of diabetes development, classified
as either occurring in the first 1.5 years of
follow-up, after 1.5 years, or never.
Ramipril allocation, baseline albumin-to-
creatinine ratio, and baseline calculated
eGFR were also included as independent
variables in these two models. Interac-
tions were tested by including an interac-
tion term in the model.
RESULTS— CVD status at trial end
was available for 98% of randomized par-
ticipants. A final visit urine albumin-to-
creatinine value and a serum creatinine
value were available for 4,106 (78%) and
4,236 (80%) participants, respectively.
Compared with the participants who had
a final renal ascertainment, those who did
not were younger (53.5 vs. 55.0 years,
P  0.0013), more likely to be women
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(62.1 vs. 58.6%, P 0.042), had a lower
fasting plasma glucose (5.78 vs. 5.85
mmol/l, P 0.004), a higher 2-h glucose
level (8.80 vs. 8.66 mmol/l, P 0.006), a
lower serum creatinine (74.3 vs. 75.7 mg/
dl, P  0.04), were more likely to be
smokers (14.8 vs. 11.6%, P 0.004), and
took less aspirin (12.1 vs. 14.8%, P 
0.023) and lipid-lowering agents (12.5
vs. 15.4%, P  0.020).
Cardiorenal outcome
During the 3-year follow-up, 836 partici-
pants had a first occurrence of the com-
posite cardiorenal outcome, comprising
133 (2.5%) cardiovascular composite
outcomes and 718 (13.6%) renal com-
posite outcomes. The composite cardio-
renal outcome occurred in 1) 412 of
2,623 (15.7%) participants allocated to
ramipril and 424 of 2,646 (16.0%) partic-
ipants allocated to placebo (HR 0.98
[95% CI 0.84–1.13]; P  0.75) and 2)
394 of 2,635 (15.0%) participants allo-
cated to rosiglitazone and 442 of 2,634
(16.8%) allocated to placebo (0.87 [0.75–
1.01]; P 0.07). The baseline character-
istics of the participants with and without
cardiorenal events and their components
are shown in Table 1. There was no sta-
tistically significant interaction between
the effects of ramipril and rosiglitazone on
the cardiorenal outcome (P  0.09).
Event rates by each cell of the factorial
design were 1) 15.6% (204 of 1,310) for
rosiglitazone and ramipril, 2) 15.7% (207
of 1,313) for ramipril and placebo, 3)
14.3% (189 of 1,325) for rosiglitazone
and placebo, and 4) 17.8% (235 of 1,321)
for placebo and placebo.
Cardiovascular component
Ramipril did not alter the rate of cardio-
vascular events or the composite of car-
diovascular death, nonfatal MI or stroke,
or any individual cardiovascualr event.
Similarly, rosiglitazone did not reduce the
overall risk of cardiovascular events but
significantly increased the risk for heart
failure (Table 2). There was no interaction
for the cardiovascular component out-
comes between ramipril and rosiglitazone
(P 0.07). Event rates by each cell of the
factorial design were 3.4% (45 of 1,310)
for rosiglitazone and ramipril, 1.8% (24
of 1,313) for ramipril and placebo, 2.4%
(32 of 1,325) for rosiglitazone and pla-
cebo, and 2.4% (32 of 1,321) for placebo
and placebo.
The 16 patients who had heart failure
were at greater risk for cardiovascular
events than the other DREAM partici-
pants. They were older (67.5 vs. 54.7
years), had higher systolic blood pressure
(147.5 vs. 136.1 mmHg), and more often
had a history of hypertension (94 vs.
43%) and left ventricular hypertrophy on
ECG tracing (25 vs. 5%). They were also
taking more antiplatelets, diuretics,
-blockers, angiotensin receptor block-
ers, lipid-lowering agents, and calcium
channel blockers. Data extracted from the
Table 1—Baseline characteristics of participants with and without cardiorenal, cardiovascular, and renal outcomes
Characteristic
Cardiorenal Cardiovascular Renal
Yes No Yes No Yes No
n 836 (100) 4,433 (100) 133 (100) 5,136 (100) 718 (100) 4,551 (100)
Age (years) 57.4  11.2 54.2  10.8* 62.9  10.0 54.5  10.9* 56.4  11.1 54.4  10.9*
Women 521 (62.3) 2,599 (58.6)† 60 (45.1) 3,060 (59.6)‡ 472 (65.7) 2,648 (58.2)*
Isolated IFG 110 (13.2) 629 (14.2) 17 (12.8) 722 (14.1) 95 (13.2) 644 (14.2)
Isolated IGT 459 (54.9) 2,568 (57.9) 62 (46.6) 2,965 (57.7)§ 408 (56.8) 2,619 (57.6)
IFG 	 IGT 267 (32.0) 1,236 (27.9)† 54 (40.6) 1,449 (28.2)§ 215 (29.9) 1,288 (28.3)
Fasting blood glucose (mmol/l) 5.88  0.67 5.82  0.66† 6.01  0.66 5.83  0.66§ 5.85  0.67 5.83  0.66
2-h post 75-g glucose (mmol/l) 8.74  1.43 8.67  1.43 8.80  1.49 8.68  1.43 8.73  1.43 8.68  1.43
Serum creatinine (mmol/l) 74.5  22.2 75.6  16.5 83.7  20.5 75.3  17.4 72.9  22.0 75.9  16.7‡
Microalbuminuria 96 (11.6) 895 (20.9)* 37 (29.1) 954 (19.1)§ 62 (8.7) 929 (21.1)*
Hypercholesterolemia 307 (36.7) 1,564 (35.3) 64 (48.1) 1,807 (35.2)§ 249 (34.7) 1,622 (35.6)
History of hypertension 428 (51.2) 1,863 (42.0)* 87 (65.4) 2,204 (42.9)* 355 (49.4) 1,936 (42.5)§
Systolic blood pressure (mmHg) 138.4  17.9 135.7  18.4‡ 142.2  18.4 135.9  18.3* 137.7  17.6 135.8  18.5†
Diastolic blood pressure (mmHg) 83.4  10.4 83.4  10.9 84.1  10.6 83.4  10.8 83.3  10.4 83.4  10.8
Ankle brachial index 1.21  0.17 1.22  0.18 1.19  0.20 1.19  0.20 1.21  0.16 1.22  0.18
BMI (kg/m2) 31.0  5.7 30.9  5.6 30.5  5.6 30.9  5.6 31.0  5.6 30.9  5.6
Waist-to-hip ratio (men) 0.96  0.06 0.96  0.07 0.97  0.06 0.96  0.07 0.96  0.06 0.96  0.07
Waist-to-hip ratio (women) 0.87  0.08 0.87  0.08 0.88  0.08 0.87  0.08 0.87  0.08 0.87  0.08
Current smokers 110 (13.2) 532 (12.0) 18 (13.5) 624 (12.2) 94 (13.1) 548 (12.0)
Alanine aminotransferase units/l 27.2  14.6 29.2  16.5§ 26.9  13.6 28.9  16.3 27.2  14.8 29.1  16.5§
ECG-LVH with sign of overload 25 (3.0) 51 (1.2)* 11 (8.3) 65 (1.3)* 18.0 (2.5) 58.0 (1.3)§
Aspirin or antiplatelets 150 (18.0) 604 (13.6)‡ 33 (24.8) 721 (14.0)‡ 120 (16.7) 634 (13.9)†
Thiazide 94 (11.3) 419 (9.5) 25 (18.8) 488 (9.5)‡ 72 (10.0) 441 (9.7)
Other diuretics 71 (8.5) 203 (4.6)* 20 (15.0) 254 (5.0)* 52 (7.3) 222 (4.9)§
Aldactone 10 (1.2) 30 (0.7) 4 (3.0) 36 (0.7)§ 8 (1.1) 32 (0.7)
Angiotensin receptor blockers 48 (5.7) 238 (5.4) 14 (10.5) 272 (5.3)§ 36 (5.0) 250 (5.5)
-Blockers 174 (20.8) 738 (16.6)§ 36 (27.1) 876 (17.1)§ 143 (19.9) 769 (16.9)†
Calcium channel blockers 152 (18.2) 525 (11.8)* 35 (26.3) 642 (12.5)* 122 (17.0) 555 (12.2)‡

-Blockers 18 (2.2) 90 (2.0) 3 (2.3) 105 (2.0) 15 (2.1) 93 (2.0)
Lipid-lowering agents 132 (15.8) 648 (14.6) 32 (24.1) 748 (14.6)§ 102 (14.2) 678 (14.9)
Data are means  SD or n (%). *P  0.0001; †P  0.05; ‡P  0.001; §P  0.01. LVH, left ventricular hypertrophy.
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documentation provided for adjudication
of the 16 participants with heart failure
showed that 1) three cases were associ-
ated with severe valvular heart disease, 2)
four were associated with an acute coro-
nary syndrome, 3) two were associated
with a left ventricular ejection fraction
40%, and 4) two were associated with
atrial fibrillation. Of 14 participants who
developed heart failure on rosiglitazone,
medication was discontinued in 9 sub-
jects, 2 subjects died (1 postoperatively
following aortic valve replacement and
coronary artery bypass graft surgery and 1
due to acute MI associated with the heart
failure), and 1 subject with renal failure
had recurrent heart failure despite having
discontinued rosiglitazone at the time of
the first episode.
Renal component
Ramipril did not alter the renal compo-
nent of the composite outcome (Table 3).
Rosiglitazone reduced this component by
20% due to a reduction in progression of
albuminuria, but the fall in eGFR by
30% was not significant (Table 3). In a
logistic model that also included rosigli-
tazone allocation, ramipril allocation,
baseline albumin/creatinine ratio, and the
baseline eGFR, the renal outcome was in-
dependently associated with both inci-
dent diabetes (HR 1.42 [95% CI 1.16–
1.74]; P  0.001) and allocation to
rosiglitazone (0.83 [0.70 – 0.98]; P 
0.027); this HR remained unchanged
when incident diabetes was replaced by
mean fasting plasma glucose in the equa-
tion. This possible relationship between
prevention of diabetes with rosiglitazone
and prevention of the renal outcome was
explored by replacing diabetes by time of
diabetes development. After controlling
for allocation to rosiglitazone and the
other variables, developing diabetes
within the first 1.5 years of follow-up was
associated with a 1.59-fold higher risk of
the renal outcome (95% CI 1.16–2.17)
(P 0.0039) versus remaining free of di-
abetes; developing diabetes after 1.5 years
was associated with a 1.34-fold higher
risk (1.05–1.71) (P 0.0019). There was
no interaction for the renal component
outcomes between ramipril and rosiglita-
zone (P 0.2). Event rates by each cell of
the factorial design were 1) 12.7% (166 of
1,310) for rosiglitazone and ramipril, 2)
14.2% (186 of 1,313) for ramipril and
placebo, 3) 11.8% (157 of 1,325) for ros-
iglitazone and placebo, and 4) 15.7%
(208 of 1,321) for placebo and placebo.
CONCLUSIONS— The DREAM trial
excluded people with IFG and/or IGT
who had CVD because of the known ben-
efits of ramipril on CVD. As such, when
the trial was designed 1) it was recognized
that there would be a low CVD event rate
that would not provide sufficient power
to detect even modest effects on CVD (an
assumption confirmed by the low 2.5%
CVD incidence) and 2) a composite car-
diorenal secondary outcome that would
yield a higher event rate was prespecified.
Neither ramipril nor rosiglitazone signifi-
cantly affected this cardiorenal composite
outcome, and ramipril did not alter its
cardiovascular or renal components.
However, rosiglitazone significantly re-
duced the renal component of this out-
come but increased the risk of heart
failure.
The fact that ramipril reduces cardio-
vascular outcomes and progression of al-
buminuria in people at high risk of CVD
has been clearly shown in the HOPE
study (10,11). This effect was attributed
to the modulat ion of the renin-
Table 2—Cardiovascular component of the cardiorenal composite
Event Ramipril Placebo HR (95% CI) Rosiglitazone Placebo HR (95% CI)
Cardiovascular composite 69 (2.6) 64 (2.4) 1.09 (0.78–1.53)* 77 (2.9) 56 (2.1) 1.38 (0.98–1.95)†
Cardiovascular death 12 (0.5) 10 (0.4) 1.21 (0.52–2.80) 12 (0.5) 10 (0.4) 1.20 (0.52–2.77)
MI 14 (0.5) 11 (0.4) 1.29 (0.59–2.84) 16 (0.6) 9 (0.3) 1.78 (0.79–4.03)
Stroke 4 (0.2) 8 (0.3) 0.50 (0.15–1.66) 7 (0.3) 5 (0.2) 1.40 (0.44–4.40)
Congestive heart failure 12 (0.5) 4 (0.2) 3.06 (0.99–9.48) 14 (0.5) 2 (0.1) 7.04 (1.60–31.0)
Revascularization 28 (1.1) 38 (1.4) 0.74 (0.46–1.21) 37 (1.4) 29 (1.1) 1.27 (0.78–2.07)
New angina 24 (0.9) 20 (0.8) 1.21 (0.67–2.19) 24 (0.9) 20 (0.8) 1.20 (0.66–2.17)
Cardiovascular death, MI, or stroke 27 (1.0) 29 (1.1) 0.94 (0.56–1.59)* 33 (1.3) 23 (0.9) 1.43 (0.84–2.44)*
Total mortality 31 (1.2) 32 (1.2) 0.98 (0.60–1.61)* 30 (1.1) 33 (1.3) 0.91 (0.56–1.49)*
Data are n (%) unless otherwise indicated. Revascularization  interventions on either coronary or peripheral arteries. The cardiovascular composite outcome
represents the first occurrence of cardiovascular death, MI, or stroke. For the other individual events, all participants with an event are included in each row. *P
0.1; †P  0.067
Table 3—Renal component of the cardiorenal composite
Event Ramipril Placebo HR (95% CI) Rosiglitazone Placebo HR (95% CI)
Renal composite 353 (13.5) 365 (13.8) 0.97 (0.83–1.14)* 324 (12.3) 394 (15.0) 0.80 (0.68–0.93)†
Albuminuria progression 267 (10.2) 287 (10.9) 0.93 (0.78–1.11)* 253 (9.6) 301 (11.4) 0.82 (0.69–0.98)‡
Normal to microalbuminuria 253 (9.7) 273 (10.3) 0.93 (0.77–1.11) 241 (9.2) 285 (10.8) 0.83 (0.69–0.99)
Normal to proteinuria 5 (0.19) 4 (0.15) 1.26 (0.34–4.71) 6 (0.23) 3 (0.11) 2.00 (0.50–8.01)
MA to proteinuria 9 (0.34) 10 (0.39) 0.91 (0.37–2.24) 6 (0.23) 13 (0.49) 0.46 (0.18–1.21)
Decreased eGFR 30% 99 (3.8) 88 (3.3) 1.14 (0.85–1.53)* 82 (3.1) 105 (4.0) 0.77 (0.58–1.04)§
Microalbuminuria regression to normal 204 (53.7) 174 (47.3) 1.30 (0.98–1.74) 193 (52.5) 185 (48.7) 1.18 (0.88–1.57)*
Data are n (%) unless otherwise indicated. The renal component of the composite is the first occurrence of any of progression of albuminuria, decreased eGFR by
30%, or renal insufficiency requiring dialysis or transplantation. For the other individual events, all participants with this event are included in each row. *P 
0.1; †P  0.005; ‡P  0.031; §P  0.087; P  0.073.
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angiotensin aldosterone system. The ab-
sence of such benefit in the DREAM trial
may have been due to the low incidence of
CVD (the composite of cardiovascular
death, MI, or stroke was documented in
only 1% [56 of 5,269] compared with
16% [1,477 of 9,297] in the HOPE study)
and the relatively short follow-up of 3
years compared with 4.5 years in the
HOPE. Moreover, as the low-risk DREAM
participants may have low activation of
the renin-angiotensin system, further in-
hibition with ramipril would be expected
to have a minimal effect.
Diabetes is a strong risk factor for re-
nal disease. As the glucose criteria used to
diagnose diabetes represent thresholds
above which the risk of retinal and renal
disease rises rapidly, an intervention that
reduces the incidence of diabetes (and
therefore the rise of glucose levels past the
diabetes thresholds) may also reduce re-
nal disease. This possibility is strongly
supported by the following finding: ros-
iglitazone, which clearly reduced the risk
of diabetes, also reduced the risk of renal
disease by 20% versus placebo, with con-
sistent changes of the renal outcome. It is
also supported by the regression models
in which incident diabetes, time of devel-
opment of diabetes (before or after 1.5
years), and rosiglitazone allocation were
independently associated with the renal
outcome. Whether additional effects be-
yond improved metabolic control con-
tributed to the renal effects observed
cannot be determined from the present
findings.
Rosiglitazone clearly increased the
risk of heart failure. Such an effect has
been repeatedly noted in other thiazo-
lidinedione studies (12–16) and appears
to be due to sodium and water retention at
the renal collecting duct noted above, an
increased plasma renin activity (17–19)
perhaps related in part to a modest fall in
blood pressure (20,21), and increased in-
sulin action (20). Two echocardiographic
studies (22,23) showed that rosiglitazone
did not significantly reduce left systolic
ventricular function. Of note is the fact
that the actual 0.5% incidence of heart
failure with rosiglitazone during this
3-year trial of people at low risk for car-
diovascular outcomes was lower than the
1.5% (12), 1.7% (15), and 5.7% (16) in-
cidence reported in similar length thiazo-
lidinedione trials of people at higher risk
of cardiovascular outcomes. Neverthe-
less, the high relative risk of heart failure
represents new evidence that low-risk
people are not protected from this side
effect.
The lack of a clear cardiorenal benefit
(due to no effect on the cardiovascular
component of the composite) was sur-
prising in light of the many favorable ef-
fects of rosiglitazone on surrogate
markers of CVD (15,20,21,24). It is pos-
sible that the short follow-up period and
the low cardiovascular outcome inci-
dence were insufficient to allow a modest
cardiovascular effect to emerge. Alterna-
tively, rosiglitazone may have a neutral
effect on ischemic CVD events. Indeed,
there have been recent concerns that it
may increase the risk of ischemic CVD
(25), but the absence of any clear cardio-
vascular benefit or harm of rosiglitazone
in an interim analysis of a large cardiovas-
cular trial (15) have fueled uncertainty re-
garding its effects on ischemic CVD and
highlight the need for large trials with suf-
ficient power to resolve this dilemma.
Strengths of our study include the fact
that all of the measured outcomes were
prospectively defined, collected, and ad-
judicated. The findings are limited by the
fact that renal outcomes were only avail-
able in 78% of participants at study end.
In summary, the DREAM trial
showed no significant impact of ramipril
on the composite cardiorenal outcome or
its cardiovascular or renal components. It
also did not show an effect of rosiglita-
zone on the cardiorenal outcome or its
cardiovascular component, but it in-
creased heart failure. However, rosiglita-
zone did reduce the renal component of
this outcome, one of the consequences of
diabetes, in addition to reducing the inci-
dence of diabetes itself.
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